Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4944)
All Articles published online
|
Publishing Process of This Article
|
Jul 28, 2022 (publication date) through May 27, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Tanaka T, Sakai A, Tsujimae M, Yamada Y, Kobayashi T, Masuda A, Kodama Y. Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report. World J Gastroenterol 2022; 28(28): 3732-3738 [PMID: 36161046 DOI: 10.3748/wjg.v28.i28.3732] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i28/3732.htm |
| Number | Citing Articles |
| 1 |
Jose M. Pinazo-Bandera, Juan Pedro Toro-Ortiz, Raúl J. Andrade, Miren García-Cortés. Drug-induced cholestasis: causative agents and challenges in diagnosis and management. Exploration of Digestive Diseases 2023; 2(5): 202 doi: 10.37349/edd.2023.00027
|
| 2 |
Xiangchen Meng, Jiafei Peng, Hongtao Wei. Etiology and Clinical Features of Secondary Sclerosing Cholangitis: A Single‐Center Retrospective Study From 2016 to 2024. JGH Open 2025; 9(2) doi: 10.1002/jgh3.70122
|
| 3 |
Joshua Newington, Daniel Patterson, Pilar Sanchez. Delayed onset autoimmune cholangitis in a patient treated with pembrolizumab. BJR|Case Reports 2024; 10(6) doi: 10.1093/bjrcr/uaae040
|
| 4 |
Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Tsutomu Shinohara, Eiji Takeuchi. Late‐onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer. Thoracic Cancer 2023; 14(1): 81 doi: 10.1111/1759-7714.14736
|
| 5 |
Weilun Fang, Wei Sun, Weijin Fang, Jian Zhang, Chunjiang Wang. Clinical features, treatment, and outcome of pembrolizumab induced cholangitis. Naunyn-Schmiedeberg's Archives of Pharmacology 2024; 397(10): 7905 doi: 10.1007/s00210-024-03135-2
|
| 6 |
Einar S. Bjornsson, Harshad C. Devarbhavi. Drug-induced cholestatic liver diseases. Hepatology 2024; doi: 10.1097/HEP.0000000000001052
|
| 7 |
Zheqing Liu, Xiaojing Du, Meiling Deng, Yuanyuan Chen, Shaoxiong Wu. Successful replacement for recurrent nasopharyngeal carcinoma with cholecystitis induced by PD-1 antibody: a case report. Immunotherapy 2024; 16(14-15): 949 doi: 10.1080/1750743X.2024.2382670
|
| 8 |
Einar S. Bjornsson, Daiana Arnedillo, Fernando Bessone. Secondary Sclerosing Cholangitis due to Drugs With a Special Emphasis on Checkpoint Inhibitors. Liver International 2025; 45(4) doi: 10.1111/liv.16163
|
| 9 |
Eleonora De Martin, Claudia A M Fulgenzi, Ciro Celsa, Astrid Laurent-Bellue, Aria Torkpour, Pasquale Lombardi, Antonio D’Alessio, David J Pinato. Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events. Gut 2024; : gutjnl-2024-332125 doi: 10.1136/gutjnl-2024-332125
|
| 10 |
Lily Dara, Eleonora De Martin. Immune‐Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges. Liver International 2025; 45(2) doi: 10.1111/liv.16198
|
| 11 |
Antineoplastics/methyprednisolone. Reactions Weekly 2022; 1929(1): 92 doi: 10.1007/s40278-022-25716-5
|